The “Wegovy” brand slimming syringe is sold at the Achat pharmacy in Mitte. The slimming syringe “Wogovy” has been available in Germany for a year.
Jens Kalaene | Image Alliance | Getty images
A version of this article appeared for the first time in the Healthy Bulletin returns from CNBC, which brings the latest medical care news directly to its entrance tray. Subscribe here To receive future editions.
Another study is concentrating on the involuntary side effects of Novo NordiskSemaglutida: The active ingredient in the successful medicine to lose weight of the company, treatment of diabetes and ozempic.
But this time, the study highlights the risk of hair loss.
To be clear, the Semaglutide link with hair loss is not new. The clinical trials carried out by Novo Nordisk have shown a higher risk of hair loss in patients who took semaglutida compared to those who took a placebo.
Wegovy and Ozempic are part of a kind of popular medicines called LPG-1, which mimic a hormone in the intestine to suppress appetite and regulate blood sugar. These medications are known for their gastrointestinal side effects, such as nausea and vomiting, and have also faced greater scrutiny after some patients reported having experienced stomach paralysis and suicidal ideation while they took them.
In a statement, Novo Nordisk said that “continues to trust the risk profile of our GLP-1 medications, when used according to their indications and labeling of products.”
The new study, conducted by researchers from the University of British Columbia and that has not yet been presented for peer review, shows that the semaglutida is associated with hair loss compared to users of a older weight loss pill called contrave, or bupropion-naltrexone.
The researchers examined data from 16 million patients from 2006 to 2020 and They identified 1,926 semaglutidas and 1,348 contrave users. People were excluded with a diagnosis of diabetes or who used antihyperglycemia, medications that lower blood sugar levels.
The incidence rates of hair loss were higher among semaglutidas users than contrave users. In general, patients who took semaglutida had a higher 52% risk of hair loss compared to those who took contravas.
The researchers also found that the women who took semaglutida had more than twice the risk of hair loss compared to women in the contrave group. But Mohit Sodhi, one of the authors, told CNBC that “most of our data were driven by women” so that they cannot compare men in front of women in the study.
Among those who took semaglutida, there were 22 cases of hair loss in women and only one case in men. Future studies are needed with larger sample sizes of patients to determine if there is a difference between men and women, Sodhi said.
The researchers also follow the patients if they stopped the semaglutida or contravene, so it is not clear if the risk of hair loss decreases once they are out of Novo Nordisk's medicine, according to Sodhi. More research is required in that area, he said.
So why could the semagglutide cause a higher risk of hair loss?
A factor could be the physiological stress that rapid weight loss can induce, which can lead to the “interruption of the natural hair cycle,” according to Sodhi. He said it can be a more prominent effect of the semaglutida because it is known that the weight faster than contravene decreases.
The ability of the semaglutida to suppress the appetite also leads to patients who consume less food, which can cause nutrient deficiencies, including protein in particular, added Sodhi. It has been shown that protein deficiencies are related to hair loss, he said.
Sodhi said patients can also lose nutrients through vomiting when they are in semaglutida. Some health experts also pose the hypothesis that semaglutida can lead to hormonal changes that increase the risk of a common way of hair loss called androgenic alopecia, he added.
People, and women in particular, considering the use of strictly losing semaglutidation may want to “take into account hair loss as a possible limitation” of the medicine, the researchers said in the study. But people with diabetes or morbid obesity can weigh their risks and benefits differently, and may be more willing to accept hair loss as a potential risk, the researchers added.
One of the authors of the study, Dr. Mahyar Etminan, has previously consulted on Ozempic -related litigation.
Do not hesitate to send any advice, suggestion, stories ideas and data to Annika in [email protected].
The latest in Medical Care Technology: Dexcom receives a WAR -of -the -Warning letter, appoint a new member of the Board
The Dexcom logo is seen on the screen of a smartphone and in the background.
Pavlo Gonchanche | Soup images | LIGHTROCKET | Getty images
Dexcom He received a warning letter from the United States drug and food administration last week after the agency inspected the company's manufacturing facilities in San Diego, California and Mesa, Arizona.
The FDA “observed non -conformities” with the Dexcom quality management system and the manufacturing processes, according to a Friday company that presents before the US stock and values commission. UU. The agency also pointed out that the company's response to its list of observations, formally known as form 483, was insufficient.
“The company takes the issues identified in the warning letter seriously, it has already presented several responses to form 483 and is in the process of preparing a written response to the warning letter,” Dexcom said in the presentation.
It was not clear what specific problems identified the FDA in the facilities.
Dexcom produces devices called continuous glucose monitors that can help users track their blood sugar and control diabetes. The FDA warning letter does not limit Dexcom's ability to manufacture or distribute its products.
The company told CNBC that it has been “regularly updating” the FDA on the improvements since the agency carried out the inspections last year. Some of his observations have already been sufficiently addressed, and the warning letter detailed “specific areas for continuous approach,” said Dexcom.
“Dexcom supports the quality of our products and is committed to solving any pending FDA question as soon as possible,” said the company in a statement.
Dexcom also appointed Renée Galá, director of Operations of Jazz Pharmaceuticals, for his board of directors last week. Galá has worked on his current role since 2023, and previously served as financial director of Jazz.
He has also performed leadership functions in Grail and Theravance Biopharma, and spent several years in the pharmaceutical giant Eli Lilly.
“The extensive experience of Renée that guides global finance and global operations, including commercial and R&D operations, to boost growth and create value of the shareholders provides an excellent adjustment at this key point on the Dexcom trip,” said the CEO of Dexcom, Kevin Sayer, in a statement.
From the negotiation intradic in Tuesday morning, the actions of Dexcom have dropped approximately 9% to date.
Read the complete launch here.
Do not hesitate to send any advice, suggestion, stories ideas and data to Ashley at [email protected].
